Archimed
 
 
 
  • About Us
  • Fund
  • Support
  • Return
  • Our Companies
  • left
    • About Us
    • Our Companies
    • Our DNA
  • Fund
    • Our Investment Strategy
    • Our Investors
    • Our Funds
    • Our Charity Fund
  • Support
    • Our Value Creation
    • Our Team and Network
  • Return
    • Return to Investors
    • Return to People
    • Return to Society
  • right
    • News
    • JOIN OUR TEAM
    • Investor Portal
    • Contact

NEWS

Our Latest News

ARCHIMED completes seventh acquisition for NAMSA, the world leader in Medical Device testing services

ARCHIMED completes seventh acquisition for NAMSA, the world leader in Medical Device testing services

ARCHIMED acquires Nasdaq-listed Natus Medical Incorporated in $1.1 billion take-private deal

 July

 21, 

2022

ARCHIMED invests in Title21 Health Solutions, a leading US-based healthcare software provider

 July

 12, 

2022

ARCHIMED invests in Corealis Pharma, a North American CDMO, through MED III

 May

 24, 

2022

ARCHIMED’s MED II fund earns a 6x return on EUROLyser, its first exit

 May

 9, 

2022

ARCHIMED sells health ingredients developer Fytexia to Associated British Foods

 February

 2, 

2022

ARCHIMED buys CARSO, a leader in purity testing for pharma and other industries

 December

 16, 

2021

< 1 2 3 4 … 12 >
368
  • ARCHIMED © 2022
  • Our Eco Design Approach
  • Legal Notice
  • SFDR Disclosures
  • Contact Us
  • LinkedIn
    Go top

    Back to top